[go: up one dir, main page]

AR056762A1 - (4 -(6-halo-7- substituidos -2,4- dioxo-1,4- dihidro-2h-quinazolin-3-il- fenil)-5- cloro- tiophen-2- il sulfonilureas y formas y metodos - Google Patents

(4 -(6-halo-7- substituidos -2,4- dioxo-1,4- dihidro-2h-quinazolin-3-il- fenil)-5- cloro- tiophen-2- il sulfonilureas y formas y metodos

Info

Publication number
AR056762A1
AR056762A1 ARP060104840A ARP060104840A AR056762A1 AR 056762 A1 AR056762 A1 AR 056762A1 AR P060104840 A ARP060104840 A AR P060104840A AR P060104840 A ARP060104840 A AR P060104840A AR 056762 A1 AR056762 A1 AR 056762A1
Authority
AR
Argentina
Prior art keywords
forms
pharmaceutically acceptable
thrombosis
compounds
formula
Prior art date
Application number
ARP060104840A
Other languages
English (en)
Original Assignee
Portola Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharm Inc filed Critical Portola Pharm Inc
Publication of AR056762A1 publication Critical patent/AR056762A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

La presente proporciona novedosos compuestos de sulfonilurea de formula (1) y sus derivados farmacéuticamente aceptables y formas polimorfas y amorfas. Los compuestos en sus diversas formas son inhibidores de los receptores de ADP plaquetarios eficaces y pueden utilizarse en diversas composiciones farmacéuticas, y son particularmente eficaces para la prevencion y/o tratamiento de enfermedades cardiovasculares, particularmente aquellas enfermedades relacionadas con la trombosis. También proporciona un método para preparar ese tipo de compuestos y formas y para prevenir o tratar la trombosis y afecciones relacionadas con la trombosis en un mamífero que comprende el paso de administrar una cantidad terapéuticamente eficaz de un compuesto de formula 1) o su sal o formas farmacéuticamente aceptables. Reivindicacion 1: Un compuesto que tiene la siguiente formula (1) donde: X se selecciona entre el grupo que consiste de F e I; R1 se selecciona entre el grupo que consiste en H, halogeno, -OH, alquilo C1-10 y alquilamino C1-6 o su derivado farmacéuticamente aceptable.
ARP060104840A 2005-11-03 2006-11-03 (4 -(6-halo-7- substituidos -2,4- dioxo-1,4- dihidro-2h-quinazolin-3-il- fenil)-5- cloro- tiophen-2- il sulfonilureas y formas y metodos AR056762A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US73365005P 2005-11-03 2005-11-03

Publications (1)

Publication Number Publication Date
AR056762A1 true AR056762A1 (es) 2007-10-24

Family

ID=38023842

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060104840A AR056762A1 (es) 2005-11-03 2006-11-03 (4 -(6-halo-7- substituidos -2,4- dioxo-1,4- dihidro-2h-quinazolin-3-il- fenil)-5- cloro- tiophen-2- il sulfonilureas y formas y metodos

Country Status (20)

Country Link
US (3) US8058284B2 (es)
EP (2) EP2428514A1 (es)
JP (1) JP5509406B2 (es)
KR (1) KR101423483B1 (es)
CN (1) CN101300013B (es)
AR (1) AR056762A1 (es)
AT (1) ATE540034T1 (es)
AU (1) AU2006311795B2 (es)
BR (1) BRPI0618210A2 (es)
CA (1) CA2627719C (es)
CY (1) CY1112826T1 (es)
DK (1) DK1951254T3 (es)
EA (1) EA017402B1 (es)
ES (1) ES2380814T3 (es)
IL (1) IL191193A (es)
NZ (2) NZ567747A (es)
PT (1) PT1951254E (es)
TW (2) TW200728260A (es)
WO (2) WO2007056219A2 (es)
ZA (1) ZA200804241B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0512273A (pt) 2004-06-18 2008-02-19 Millennium Pharm Inc inibidores do fator xa
KR101423483B1 (ko) * 2005-11-03 2014-07-28 포톨라 파마슈티컬스, 인코포레이티드 〔４-(６-할로-７-치환된-２,４-디옥소-１,４-디히드로-２ｈ-퀴나졸린-３-일)-페닐〕-５-클로로티오펜-２-일-설포닐우레아 및 이의 형태 및 이와 관련된 방법
EP2016072B1 (en) 2006-05-05 2014-07-16 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
TW200911755A (en) 2007-04-19 2009-03-16 Astellas Pharma Inc Bicyclic heterocyclic compounds
EA020045B1 (ru) * 2007-05-02 2014-08-29 Портола Фармасьютиклз, Инк. Комбинированная терапия соединением, проявляющим активность ингибитора рецептора адф на тромбоцитах
US20090156620A1 (en) * 2007-05-02 2009-06-18 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto
CA2686221A1 (en) * 2007-05-02 2008-11-13 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto
KR20100029746A (ko) 2007-05-02 2010-03-17 포톨라 파마슈티컬스, 인코포레이티드 직접 작용하는 가역적인 ｐ2ｙ12 억제제의 정맥내 및 경구 투여
MX2009013431A (es) * 2007-06-18 2010-01-15 Sanofi Aventis Derivados de pirrol como antagonistas de p2y12.
CN101654441B (zh) * 2008-08-19 2012-10-03 信谊药厂 抗凝化合物、组合物及其用途
CA2743639A1 (en) * 2008-11-14 2010-05-20 Patheon Inc. Solid composition for controlled release of ionizable active agents with poor aqueous solubility at low ph and methods of use thereof
WO2011006169A1 (en) 2009-07-10 2011-01-13 Portola Pharmaceuticals, Inc. Methods for diagnosis and treatment of thrombotic disorders mediated by cyp2c19*2
JP5597202B2 (ja) 2009-08-28 2014-10-01 第一三共株式会社 ３−（ビアリールオキシ）プロピオン酸誘導体
WO2011075602A1 (en) 2009-12-17 2011-06-23 Millennium Pharmaceuticals, Inc. Methods of preparing factor xa inhibitors and salts thereof
JP5796872B2 (ja) 2009-12-17 2015-10-21 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 第Ｘａ因子阻害剤の結晶性塩
US20130165459A1 (en) 2010-01-12 2013-06-27 Norvartis Pharma Ag Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof
WO2011137459A1 (en) 2010-04-30 2011-11-03 Portola Pharmaceuticals, Inc. Dosage forms of elinogrel and methods of injectable administration thereof
EP2646434B1 (en) * 2010-12-03 2019-05-15 Portola Pharmaceuticals, Inc. Pharmaceutical compositions, dosage forms and new forms of the compound of formula (i), and methods of use thereof
WO2014042176A1 (ja) * 2012-09-14 2014-03-20 キッセイ薬品工業株式会社 縮合複素環誘導体の製造方法およびその製造中間体
RU2556198C1 (ru) * 2014-04-10 2015-07-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт кардиологии" Сибирского отделения Российской академии медицинских наук Способ профилактики развития постперикардиотомного синдрома у больных ишемической болезнью сердца, подвергшихся коронарному шунтированию
HK1255034A1 (zh) 2015-07-01 2019-08-02 Crinetics Pharmaceuticals, Inc. 生长抑素调节剂及其用途
WO2019023278A1 (en) 2017-07-25 2019-01-31 Crinetics Pharmaceuticals, Inc. MODULATORS OF SOMATOSTATIN AND USES THEREOF
EP4204418A1 (en) 2020-08-28 2023-07-05 Arvinas Operations, Inc. Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use
TW202432544A (zh) 2022-09-07 2024-08-16 美商亞文納營運公司 快速加速纖維肉瘤降解化合物及相關使用方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE845042C (de) 1950-07-14 1952-07-28 Basf Ag Verfahren zur Herstellung von Sulfonylurethanen, -harnstoffen oder -carbonsaeureamiden
US3847925A (en) * 1971-07-15 1974-11-12 En Nom Collectif Science Et Ci Benzenesulfonyl semicarbazides
DE3134780A1 (de) * 1981-09-02 1983-03-10 Hoechst Ag, 6000 Frankfurt "sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung"
US4720450A (en) * 1985-06-03 1988-01-19 Polaroid Corporation Thermal imaging method
GB9413975D0 (en) 1994-07-11 1994-08-31 Fujisawa Pharmaceutical Co New heterobicyclic derivatives
US5314902A (en) * 1993-01-27 1994-05-24 Monsanto Company Urea derivatives useful as platelet aggregation inhibitors
US6268380B1 (en) 1993-02-19 2001-07-31 G. D. Searle & Co. Urea derivatives useful as platelet aggregation inhibitors
WO1994021602A1 (en) 1993-03-15 1994-09-29 G.D. Searle & Co. Urea derivatives useful as platelet aggregation inhibitors
TW448161B (en) 1994-07-14 2001-08-01 Otsuka Pharma Co Ltd Cyclic amide derivatives
JPH0881442A (ja) 1994-07-14 1996-03-26 Otsuka Pharmaceut Co Ltd 環状アミド誘導体
US6413724B1 (en) * 1996-10-28 2002-07-02 Versicor, Inc. Solid phase and combinatorial library syntheses of fused 2,4-pyrimidinediones
US6160000A (en) * 1996-12-23 2000-12-12 Merck & Co., Inc. Antidiabetic agents based on aryl and heteroarylacetic acids
JPH10195323A (ja) 1997-01-09 1998-07-28 Nippon Paper Ind Co Ltd 新規なスルホニルグアニジン化合物及びそれを用いた感熱記録体
SE9702774D0 (sv) 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
JP2002509152A (ja) 1998-01-15 2002-03-26 シーオーアール セラピューティクス インコーポレイテッド 血小板ａｄｐ受容体阻害剤
JP2000204081A (ja) 1998-02-05 2000-07-25 Takeda Chem Ind Ltd スルホンアミド誘導体、その製造法及び用途
US6906063B2 (en) * 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
JP4574100B2 (ja) 2000-02-04 2010-11-04 ポートラ ファーマシューティカルズ， インコーポレイテッド 血小板ａｄｐレセプターインヒビター
ATE502928T1 (de) * 2000-11-01 2011-04-15 Millennium Pharm Inc Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung
US6824790B2 (en) * 2002-01-09 2004-11-30 Enzrel Inc. Liposome drug delivery of polycyclic, aromatic, antioxidant or anti-inflammatory compounds
US20040242658A1 (en) * 2003-01-08 2004-12-02 Dr. Reddy's Laboratories Limited Amorphous form of rosiglitazone maleate and process for preparation thereof
AU2004278030C1 (en) * 2003-10-03 2010-12-02 Portola Pharmaceuticals, Inc. 2,4-Dioxo-3-quinazolinylaryl sulfonylureas
KR101423483B1 (ko) 2005-11-03 2014-07-28 포톨라 파마슈티컬스, 인코포레이티드 〔４-(６-할로-７-치환된-２,４-디옥소-１,４-디히드로-２ｈ-퀴나졸린-３-일)-페닐〕-５-클로로티오펜-２-일-설포닐우레아 및 이의 형태 및 이와 관련된 방법
US20090156620A1 (en) * 2007-05-02 2009-06-18 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto
KR20100029746A (ko) * 2007-05-02 2010-03-17 포톨라 파마슈티컬스, 인코포레이티드 직접 작용하는 가역적인 ｐ2ｙ12 억제제의 정맥내 및 경구 투여
CA2686221A1 (en) * 2007-05-02 2008-11-13 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto

Also Published As

Publication number Publication date
EP2428514A1 (en) 2012-03-14
NZ596025A (en) 2013-08-30
DK1951254T3 (da) 2012-05-07
CA2627719A1 (en) 2007-05-18
EP1951254A4 (en) 2009-05-27
EA017402B1 (ru) 2012-12-28
AU2006311795B2 (en) 2013-01-17
EP1951254A2 (en) 2008-08-06
EP1951254B1 (en) 2012-01-04
KR101423483B1 (ko) 2014-07-28
NZ567747A (en) 2011-11-25
JP2009515836A (ja) 2009-04-16
US20070208045A1 (en) 2007-09-06
JP5509406B2 (ja) 2014-06-04
US8058284B2 (en) 2011-11-15
IL191193A (en) 2014-04-30
AU2006311795A1 (en) 2007-05-18
EA200801245A1 (ru) 2008-10-30
CY1112826T1 (el) 2016-02-10
TWI397529B (zh) 2013-06-01
WO2007056219A3 (en) 2007-12-27
TW200728260A (en) 2007-08-01
ES2380814T3 (es) 2012-05-18
US20120088736A1 (en) 2012-04-12
CA2627719C (en) 2016-07-12
HK1121051A1 (en) 2009-04-17
WO2007056167A2 (en) 2007-05-18
BRPI0618210A2 (pt) 2011-08-23
WO2007056167A3 (en) 2007-10-04
CN101300013B (zh) 2012-11-28
US20070123547A1 (en) 2007-05-31
PT1951254E (pt) 2012-04-12
ZA200804241B (en) 2009-09-30
WO2007056219A2 (en) 2007-05-18
KR20080071167A (ko) 2008-08-01
TW200804356A (en) 2008-01-16
CN101300013A (zh) 2008-11-05
ATE540034T1 (de) 2012-01-15

Similar Documents

Publication Publication Date Title
AR056762A1 (es) (4 -(6-halo-7- substituidos -2,4- dioxo-1,4- dihidro-2h-quinazolin-3-il- fenil)-5- cloro- tiophen-2- il sulfonilureas y formas y metodos
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
PE20060570A1 (es) Compuestos de quinazolina e isoquinolina piperidilo sustituidos como inhibidores de fosfodiesterasa pde-10
DOP2007000079A (es) Compuestos fenil amido heterocíclicos condensados
AR030959A1 (es) Derivados de aminoalcoholes, procedimiento para prepararlos, el uso de los mismos para preparar medicamentos y las composiciones farmaceuticas que las contienen
PE20060648A1 (es) Procesos para la preparacion de 2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolinas sustituidas
DK1257550T3 (da) Blodplade-ADP-receptor-inhibitor
UY28280A1 (es) 2- hidroxi - 3- diaminoalcanos de benzamida
AR043199A1 (es) Componentes heterociclicos utiles para el tratamiento de enfermedades inflamatorias y alergicas, proceso para su operacion y composicion farmaceutica que contiene dichos componentes
AR053415A1 (es) Inhibidores dipeptidil peptidasa iv, composiciones farmaceuticas que los contienen y procesos para la preparacion de los compuestos y de la composicion
AR051780A1 (es) Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
ECSP099324A (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
PE20050325A1 (es) DERIVADOS DE PIRROLO[3,4-c]PIRAZOL ACTIVOS COMO INHIBIDORES DE QUINASA, PROCESO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN
PE20220704A1 (es) Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmaceuticas que los contienen y sus usos como agentes proapoptoticos
EA200901474A1 (ru) Соли [4-(6-фтор-7-метиламино-2,4-диоксо-1,4-дигидро-2н-хиназолин-3-ил)фенил]-5-хлортиофен-2-илсульфонилмочевины в различных кристаллических формах и фармацевтические композиции на их основе
AR074353A1 (es) Acidos naftalen-2-il-aceticos sustituidos, composiciones farmaceuticas que los contienen, y uso de los mismos en el tratamiento de enfermedades alergicas,tales como rinitis, asma y dermatititis atopica.
UY26564A1 (es) Inhibidores del factor xa con aril - amidinas y sus derivados, y composiciones farmacéuticas que contienen los mismos
ATE469157T1 (de) Tetrahydrofuroä3,4-düdioxolverbindungen und zusammensetzungen und verfahren zur inhibierung der trombozytenaggregation
AR016644A1 (es) Compuestos de 2-aminopiridinas con sustituyentes alcoxi ramificados, composicion farmaceutica y uso para la manufactura de medicamentos
PE20050293A1 (es) Derivados de aminoacidos sustituidos con cicloalquilo, procedimiento para su preparacion y su uso como medicamentos
PE20120217A1 (es) Derivados de carbamatos de alquil-heterociclos, su preparacion y su aplicacion en terapeutica
EA200501148A1 (ru) Пиридилоксиметильные и бензизоксазольные азабициклические производные
AR035465A1 (es) Compuestos de imidazopiridina, procesos para su preparacion,formulacion farmaceutica, usos de estos compuestos para la fabricacion de medicamentos e intermediarios
ECSP066415A (es) 2-carbonilamino-6-piperidinaminopiridinas sustituidas y 1-carbonilamino-3-piperidinaminobenzenos sustituidos como 5-ht1f agonistas

Legal Events

Date Code Title Description
FB Suspension of granting procedure